NeoPharm Financial Statements From 2010 to 2024
| 092730 Stock | KRW 12,000 90.00 0.74% |
Check NeoPharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NeoPharm's main balance sheet or income statement drivers, such as , as well as many indicators such as . NeoPharm financial statements analysis is a perfect complement when working with NeoPharm Valuation or Volatility modules.
NeoPharm |
NeoPharm LTD Company Current Valuation Analysis
NeoPharm's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current NeoPharm Current Valuation | 153.58 B |
Most of NeoPharm's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NeoPharm LTD is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, NeoPharm LTD has a Current Valuation of 153.58 B. This is much higher than that of the Personal Products sector and significantly higher than that of the Consumer Staples industry. The current valuation for all Republic of Korea stocks is notably lower than that of the firm.
NeoPharm LTD Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining NeoPharm's current stock value. Our valuation model uses many indicators to compare NeoPharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NeoPharm competition to find correlations between indicators driving NeoPharm's intrinsic value. More Info.NeoPharm LTD is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.01 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for NeoPharm LTD is roughly 129.52 . Comparative valuation analysis is a catch-all model that can be used if you cannot value NeoPharm by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for NeoPharm's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About NeoPharm Financial Statements
NeoPharm stakeholders use historical fundamental indicators, such as NeoPharm's revenue or net income, to determine how well the company is positioned to perform in the future. Although NeoPharm investors may analyze each financial statement separately, they are all interrelated. For example, changes in NeoPharm's assets and liabilities are reflected in the revenues and expenses on NeoPharm's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in NeoPharm LTD. Please read more on our technical analysis and fundamental analysis pages.
,Ltd. manufactures and sells skin care products in Korea and internationally. ,Ltd. was founded in 2000 and is headquartered in Daejeon, South Korea. Neopharm is traded on Korean Securities Dealers Automated Quotations in South Korea.
Other Information on Investing in NeoPharm Stock
NeoPharm financial ratios help investors to determine whether NeoPharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NeoPharm with respect to the benefits of owning NeoPharm security.